Penghua CSI HK Connect Health Care Composite ETF

Hospital Authority Converts Certain Drugs to Specialized and Includes New Drugs in Medicine Register

Hong Kong Government Announces Increased Healthcare Budget and Implementation of Multiple Measures for 2026-27 Fiscal Year

Hong Kong NPC Deputies Emphasize Aligning with National Strategy to Promote Medical Innovation and International Medical Hub Development

516500

159837

512290

159992

513700

159849

510660

588130

516930

Microbiotica announced positive results from its phase 1b MELODY-1 trial of MB097 for advanced melanoma, meeting all objectives. The trial involved 41 patients and showed MB097's safety and early efficacy when combined with pembrolizumab. The nine-strain bacterial consortium demonstrated robust engraftment, especially with vancomycin preconditioning. The results support further studies in a broader patient population, aiming to enhance responses to anti-PD-1 therapy.

PharmaTimes

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

BlackRock, Inc.

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Yinhua CSI Innovative Drugs Industry ETF

iShares Global Healthcare

Ark Genomic Revolution ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

iShares US Pharma

iShares Biotechnology ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

China Merchants CSI Biotechnology Theme ETF

Invesco Biotechnology & Genome ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

VG Health

Direxion S&P Biotech Bull 3X

China Southern Hang Seng Biotech ETF(QDII)

SPDR S&P Biotech

VanEck Biotech ETF

Bosera Hang Seng Health Care ETF(QDII)

Proshares UltraShort Nasdaq Biotech

Huaan Hang Seng Biotech ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Health Care Select Sector SPDR

Microbiotica reports positive results for MB097 in advanced melanoma

02268

WXXWY

02269

Earendil Labs has announced the successful dosing of the first cohort in a Phase I clinical trial for HXN-1011, a novel biparatopic antibody targeting Thymic Stromal Lymphopoietin (TSLP). This antibody shows high affinity and blocks TSLP receptor interactions, demonstrating potent activity in preclinical studies. The company aims to develop innovative treatments for various immunological disorders, emphasizing their commitment to advancing next-generation biologics therapies.

prnewswire

WUXI XDC

WuXi Biologics

WUXI BIO

Sanofi

Bosera Hang Seng SCHK Innovative Drug Select ETF

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

520500

TransThera Sciences (Nanjing), Inc. is raising HK$156 million through a placement of 3,836,000 new H shares at HK$40.83 each, an 18% discount to market prices. This represents 1.24% of its existing H-share capital and aims to broaden the shareholder base despite modest dilution for current holders. The transaction is subject to regulatory approvals and may not complete, posing execution risks as the company seeks capital for operations and strategic plans.

Tip Ranks

China Universal CNI HK Connect Innovative Drugs Industry ETF

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

TRANSTHERA-B

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Hwabao WP CSI Pharmaceuticals ETF

TransThera reports promising tinengotinib results in advanced solid tumors

02509

603259

JPMorgan's report highlights the National Healthcare Security Administration's new plan for the 2026 National Reimbursement Drug List, which allows drugs to apply for NRDL inclusion before formal approval. This change is expected to enhance the commercialization prospects for innovative drug developers in China. The report identifies INNOVENT BIO, WUXI APPTEC, WUXI XDC, and SKB BIO as top picks, benefiting from clearer pricing rules and faster market access for high-priced drugs.

AASTOCKS News

QYUNS-B

WuXi AppTec

WUXI APPTEC

SKB BIO

TEDA BIOMEDICAL

INNOVENT BIO

ICBCCS SSE STAR Biology and Medicine ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO

02616

CStone Pharmaceuticals has launched nationwide supply of its domestically produced pralsetinib capsules in China, enhancing local supply chain for this cancer therapy. The drug's sales surged over 430% year-on-year, with expectations to exceed RMB 300 million in 2026. This move aims to meet rising clinical demand and improve cost efficiency. Pralsetinib is approved for RET fusion-positive non-small cell lung cancer and thyroid cancer, reinforcing CStone's position in precision oncology in the region.

CSTONE PHARMA-B

Founder Fubon CSI Medicine and Medical Device Innovation ETF

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

An AI tool by DeepMind has identified vorinostat, a cancer drug, as a potential treatment for liver fibrosis, marking a significant advancement in anti-fibrotic therapy research. With millions affected, this breakthrough highlights AI's potential to transform drug discovery and medical research.

Unusual Whales

AI tool helps identify cancer drug vorinostat as potential liver fibrosis treatment, advancing anti-fibrotic therapy research.

01952

On May 14, 2026, Wei Fu, a substantial shareholder of Everest Medicines, purchased 660,000 shares for approximately HK$20.7 million, marking his second acquisition this year. His previous purchase was on March 27, acquiring 860,000 shares. These actions reflect his confidence in the company's strategic direction and operational achievements, as Everest aims for over RMB15 billion in revenue by 2030. The company reported a 142% revenue increase in 2025, achieving profitability for the first time and strong sales in its innovative drugs.

Asian Corporate Newswire

EVEREST MED

Yinhua CNI HK Connect Innovative Drugs ETF

Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence

09995

688331

RemeGen Co. Ltd. plans to amend its articles of association to increase registered capital and total issued A shares due to its 2022 and 2023 Restricted A Share Incentive Schemes. The company will also update internal governance documents to enhance compliance and internal controls, with changes to be approved at the 2025 annual general meeting. This move aims to align governance with regulatory guidelines and improve oversight of board operations and executive pay.

REMEGEN

RemeGen

RemeGen Plans Governance and Articles Overhaul Following Share Incentive Issuances

01011

China NT Pharma Group Co., Ltd. disclosed details regarding the resignation of independent non-executive director Mr. Ng Ming Kwan, who cited governance issues and lack of involvement in key transactions as reasons for his departure. He raised concerns about the accuracy of disclosures and internal compliance processes. The board noted that Mr. Ng's statement reflects his views and is reviewing the issues he raised, indicating potential ongoing scrutiny of governance and compliance practices.

NT PHARMA

China Universal 800 Health Care ETF

China NT Pharma Discloses Governance Dispute Behind Director’s Resignation

Penghua CSI HK Connect Health Care Composite ETF(513700.SH)

Microbiotica reports positive results for MB097 in advanced melanoma

07:00 ETEarendil Labs Announces First Cohort Dosed in Phase I Study of Novel Biparatopic Antibody Targeting Thymic Stromal Lymphopoietin (TSLP)

TransThera Sciences to Raise HK$156 Million via Discounted H-Share Placement

TransThera reports promising tinengotinib results in advanced solid tumors

JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO